Answers are grounded in this paper and cite their sources.
BCMA is a suitable target for CAR-expressing T cells, and adoptive transfer of anti-BCMA-CAR-expressing T cells is a promising new strategy for treating multiple myeloma.
No takes yet. Share an insight, caveat, or question.
Carpenter et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: